Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bassline Productions Inc (CE) | BSSP | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.000001 | 0.000001 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 0.000001 - 0.0001 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.000001 | USD |
Bassline Productions Inc (CE) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 4.11k | 4.11B | -415.74M | $ - | $ - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
946.00 | $ - | - | - | - |
Bassline Productions (CE) News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSSP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.000001 | 0.000001 | 0.000001 | 0.000001 | 4,324,744 | 0.00 | 0.0% |
3 Months | 0.000001 | 0.0001 | 0.000001 | 0.0000356 | 3,519,195 | 0.00 | 0.0% |
6 Months | 0.000001 | 0.0001 | 0.000001 | 0.0000282 | 1,944,631 | 0.00 | 0.0% |
1 Year | 0.000001 | 0.0001 | 0.000001 | 0.000071 | 3,414,025 | 0.00 | 0.0% |
3 Years | 0.0001 | 0.0053 | 0.000001 | 0.0013618 | 95,195,337 | -0.0001 | -99.0% |
5 Years | 0.0001 | 0.0053 | 0.000001 | 0.0012839 | 76,649,873 | -0.0001 | -99.0% |
Bassline Productions (CE) Description
The Company as of 2021 is now in process of seeking a merger or acquisition candidate and working to bring the Company current. Effective October 9, 2017 the PSA Agreement with Canteck Pharma, inc. was rescinded do inability to proceed with the license for Mexico that previously had focused on its immunotherapeutic based technology specific to Cancer indication. |